Envestnet Asset Management Inc. Sells 95,471 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Envestnet Asset Management Inc. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 814,226 shares of the medical research company's stock after selling 95,471 shares during the period. Envestnet Asset Management Inc. owned about 0.21% of Thermo Fisher Scientific worth $423,585,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Howard Capital Management Group LLC boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after buying an additional 286 shares during the last quarter. Principal Financial Group Inc. boosted its position in Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after purchasing an additional 225,568 shares during the last quarter. EP Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 8.3% during the 3rd quarter. EP Wealth Advisors LLC now owns 16,236 shares of the medical research company's stock worth $10,043,000 after purchasing an additional 1,245 shares during the last quarter. National Bank of Canada FI raised its stake in shares of Thermo Fisher Scientific by 66.9% during the 3rd quarter. National Bank of Canada FI now owns 646,692 shares of the medical research company's stock worth $400,024,000 after purchasing an additional 259,123 shares in the last quarter. Finally, Zacks Investment Management grew its stake in shares of Thermo Fisher Scientific by 12.9% in the third quarter. Zacks Investment Management now owns 45,733 shares of the medical research company's stock valued at $28,289,000 after buying an additional 5,236 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Remove Ads

Thermo Fisher Scientific Price Performance

TMO stock traded up $10.05 during midday trading on Friday, reaching $437.49. The company had a trading volume of 1,036,193 shares, compared to its average volume of 1,689,227. The company has a market capitalization of $165.05 billion, a price-to-earnings ratio of 26.42, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The stock has a 50 day moving average price of $513.41 and a 200-day moving average price of $540.46.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 over the last 90 days. Insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research note on Monday, February 3rd. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research report on Friday, January 31st. Wells Fargo & Company lifted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Finally, Raymond James restated an "outperform" rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.